ABT heads into its July 15 earnings date with a notable insider buying cluster and analysts anchored above the current price — even as the stock trades well below pre-April levels.
The most interesting signal this week is what insiders did when the stock sold off. Three buyers stepped in during April and May. An independent director paid roughly $927k for 10,000 shares at $92.65 on April 27. The CFO, Philip Boudreau, bought 2,200 shares at $91.50 on April 23. A director added another 2,000 shares at $86.82 in early May. Net insider activity over the past 90 days runs to roughly $9.99 million of net buying — a notable cluster relative to the routine selling seen earlier in the year at prices around $115–116. The CFO buying open-market shares within days of an earnings release, at a price nearly 22% below where executives were selling in March, is worth flagging.
The Street still sees meaningful upside, though targets have been pared. Following the April earnings reaction — the stock fell 4.7% on the day and extended to an 8.9% loss over five sessions — analysts largely held ratings but trimmed price targets. BofA cut to $120 from $150 while keeping a Buy. Piper Sandler lowered to $115 from $135, maintaining Overweight, and reiterated that view again this week. The mean target now stands at roughly $116.50, implying about 29% upside from the current $90.53. Bulls point to cardiovascular and diabetes device market growth, international expansion, and a diversified revenue base. Bears cite competitive pressure in medical devices, diagnostics stagnation, and currency risk. The factor picture is mixed: the dividend score ranks in the 98th percentile, reflecting ABT's position as a payer with a long track record, while EPS surprise ranks only in the 29th percentile — consistent with the difficult April print.
Short interest offers no meaningful signal here. At 1.3% of the free float, there is virtually no bearish conviction in the lending market. Borrow availability is exceptionally loose — over 9,700% relative to outstanding short interest — meaning more than 1.7 billion shares remain available to lend. Cost to borrow has fallen sharply over the week, dropping to 0.26% from around 0.40% seven days ago, the lowest point in recent weeks. The ORTEX short score of 29.3 sits well below stress territory. Options are equally calm: the put/call ratio at 0.70 is essentially in line with its 20-day average of 0.69, and the z-score of 0.43 indicates no unusual hedging demand ahead of earnings. Positioning here is almost entirely indifferent rather than cautious.
The institutional base is stable and large. BlackRock reported roughly 145 million shares — 8.3% of outstanding — as of late May, with a small add. Capital Research added 1.6 million shares. Charles Schwab Investment Management made the largest proportional move in the top-holder list, adding over 32 million shares in the most recent reporting period. These are passive and semi-passive flows rather than active conviction bets, but they underline the stock's role as a core healthcare allocation.
With Q2 results due July 15, the setup is shaped more by the gap between insider buying levels in the $87–93 range and a consensus target approaching $117 than by any short-side pressure. The earnings reaction history — a sharp one-day drop and a prolonged five-day slide in April — will keep options traders alert in the days ahead, even if that anxiety is not yet visible in current PCR readings.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
